Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Let’s face it, for most pet parents, the moment the veterinarian prescribes medication for your beloved dog or cat, a little ...

Henan Key Laboratory of Nanomedicine for Targeting Diagnosis and Treatment, Zhengzhou 450001, China State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, Zhengzhou University, Zhengzhou 450001 ...

Novo Nordisk (NYSE:NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...

But drug manufacturers and researchers recognize the perks of pills. An oral version of these drugs—which are known as glucagon-like peptide 1 (GLP-1) receptor agonists—could be more ...

Drugmaker Eli Lilly (LLY-4.22%) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug had successfully completed the ...

EDITOR’S NOTE: A video that was previously attached to this article has been removed because it contained incorrect information. We apologize for the error ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

Analyst calls orforglipron a potential “Ozempic in a pill." At the highest 36mg dose, patients saw an average weight reduction of 7.9% over 40 weeks. Get prepared for the Fed’s next move ...

Eli Lilly adds that Orforglipron is the first oral small-molecule glucagon-like ... Also Read: Eli Lilly’s Mounjaro Launch Triggers Weight-Loss Drug Craze In India, Novo Nordisk Seeks To Move ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...